LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Recurrent Mutation Linked to Childhood Blindness

By LabMedica International staff writers
Posted on 29 May 2017
Image: Scientists have identified a genetic mutation that contributes to sight loss in children (Photo courtesy of the University of Edinburgh).
Image: Scientists have identified a genetic mutation that contributes to sight loss in children (Photo courtesy of the University of Edinburgh).
Researchers have identified a genetic mutation that contributes to the sight loss that occurs in children with ocular coloboma, a developmental defect that causes part of the eye to be missing at birth. The findings shed light on its causes and help explain how genes contribute to development of the eye.

Ocular coloboma is a developmental defect in optic fissure closure and is a common cause of severe congenital visual impairment. Coloboma can have profound, devastating effects on visual ability, accounting for up to 10% of all childhood blindness. It can cause a distinctive keyhole-shaped pupil as it commonly results in a missing segment in the iris. However, coloboma is very variable and therefore likely to be caused by a number of genes. Few genetic causes have so far been found to help explain the cause of coloboma.

The research team, led by Dr. Joe Rainger University of Edinburgh, worked with 12 families, studying the DNA of children with coloboma and their unaffected parents. Using state-of-the-art genetic screening by whole exome sequencing, the scientists revealed mutations in 10 genes, 3 of which were linked to activity of one molecule: actin, important for various vital cell functions, including in defining cell shape and structure via maintenance of the cytoskeleton.

Targeted gene sequencing was then carried out on a further 380 people with coloboma. This showed that one of the mutations – a specific alteration in the gene ACTG1 – recurred across a number of those tested. The scientists edited this ACTG1 mutation into a line of mice using cutting-edge CRISPR/Cas9 gene-editing technology, and found that it had severe effects on actin function.

The newly identified mutations are thought to affect how actin binds to other proteins and on actin stability, which could severely affect development of the eye in the womb. The findings add knowledge to our understanding of coloboma onset as well as on the importance of actin to eye development.

The study, by Rainger J et al, was published May 11, 2017, in the journal Human Mutation.

New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Laboratory Software
ArtelWare

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more